Literature DB >> 1812040

Phospholipase A2 activity of colonic mucosa in patients with ulcerative colitis.

S Almer1, L Franzén, G Olaison, K Smedh, M Ström.   

Abstract

Activation of enzyme phospholipase A2 (EC 3.1.1.4), the major liberator of arachidonic acid, has been proposed as a component in the pathogenesis of inflammatory bowel disease. To test the hypothesis that phospholipase A2 activity is increased in ulcerative colitis, enzyme activity was investigated in colonic biopsies using radiolabelled Escherichia coli as substrate. The study comprised patients with ulcerative colitis (n = 19) and controls without inflammatory bowel disease (n = 7). Ulcerative colitis patients were grouped into those with active disease (n = 8) and those in remission (n = 11) at the time of colonoscopy. No differences were found in mucosal phospholipase A2 activity between patients with active disease, patients in remission and controls. With the present assay we were unable to demonstrate activation of phospholipase A2 as a mechanism in the inflammatory process of ulcerative colitis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1812040     DOI: 10.1159/000200753

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  3 in total

1.  Increased group II phospholipase A2 in colonic mucosa of patients with Crohn's disease and ulcerative colitis.

Authors:  T Minami; H Tojo; Y Shinomura; Y Matsuzawa; M Okamoto
Journal:  Gut       Date:  1994-11       Impact factor: 23.059

2.  D-dimer improves the prognostic value of combined clinical and laboratory data in equine gastrointestinal colic.

Authors:  M Sandholm; A Vidovic; A Puotunen-Reinert; S Sankari; K Nyholm; H Rita
Journal:  Acta Vet Scand       Date:  1995       Impact factor: 1.695

3.  Metabolomic Signatures in Pediatric Crohn's Disease Patients with Mild or Quiescent Disease Treated with Partial Enteral Nutrition: A Feasibility Study.

Authors:  Jair Gonzalez Marques; Engy Shokry; Klara Frivolt; Katharina Julia Werkstetter; Annecarin Brückner; Tobias Schwerd; Sibylle Koletzko; Berthold Koletzko
Journal:  SLAS Technol       Date:  2020-11-18       Impact factor: 3.047

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.